Scholar Rock Holding Corporation reported $0 of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $0 (to Q2 2026). Net income: −$409M, trailing twelve months to Q2 2026. Free cash flow: −$297M, trailing twelve months to Q2 2026. EPS: −$3.32, trailing twelve months to Q2 2026.

SRRKScholar Rock Holding Corporation

Healthcare

$42.22+37% 1Y

$42.22

$27.9252 weeks$60.01

SRRK as reported

Scholar Rock Holding Corporation reported $0 of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.

Revenue, trailing twelve months · to Q2 2026 · every figure below is as filed, with no scoring applied

Net income: −$409M
Net income · +29% year on year · trailing twelve months to Q2 2026
Free cash flow: −$297M
Free cash flow · +15% year on year · trailing twelve months to Q2 2026
EPS: −$3.32
EPS · +14% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for SRRK, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$0	n/a	Q2 2026
Net income	−$409M	+29%	Q2 2026
EPS	−$3.32	+14%	Q2 2026
Operating margin	−558%	n/a	Q1 2022 · 17 quarters behind
Net margin	−566%	n/a	Q1 2022 · 17 quarters behind
ROE	−152%	n/a	Q2 2026
ROA	−83%	n/a	Q2 2026
ROIC	1922%	n/a	Q2 2026
Free cash flow	−$297M	+15%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.